talkbio – Page 10

FDA Leaders Anticipate Imminent Drug Approval Decisions

3 weeks ago talkbio0Tagged approvals, Drug Approval, Leadership, PDUFA, regulatory decision, United States Food and Drug Administration

FDA; drug approval; PDUFA date; regulatory decision; upcoming approvals; FDA leadership

Novo Nordisk Signs $812M Deal with Deep Apple to Develop Non-Incretin Obesity Drugs

3 weeks ago talkbio0Tagged cardiometabolic disease, Deep Apple, Drug Discovery, G-Protein-Coupled Receptors, Non-Incretin, Nordisk, Obesity, research collaboration, Small Molecule

Novo Nordisk; Deep Apple Therapeutics; obesity; non-incretin; GPCR; cardiometabolic disease; small molecules; research collaboration; deal; drug discovery

Novo Nordisk Strikes Major Deal with Deep Apple Therapeutics for Oral Cardiometabolic Medicines

4 weeks ago talkbio0Tagged biotech partnership, cardiometabolic diseases, Collaboration, Deep Apple, G-Protein-Coupled Receptors, Nordisk, Obesity, Oral Medicine, R&D, small molecule therapeutics, Target

Novo Nordisk; Deep Apple Therapeutics; cardiometabolic diseases; oral medicines; obesity; small molecule therapeutics; GPCR target; R&D collaboration; biotech partnership

Organoid Startup Raises $21M to Test Drugs and Vaccines in Human Lymph Nodes-in-a-Dish

4 weeks ago talkbio0Tagged biotech startup, Homo sapiens, lymph nodes, Organoids, research funding, Substance Abuse Detection, tissue models, Vaccine Testing

organoids; lymph nodes; drug testing; vaccine testing; biotech startup; research funding; human tissue models

Best Practice Customer-Facing Organization Study Report (2025) – Key Findings and Trends

4 weeks ago talkbio0Tagged Aortic Valve Insufficiency, Customer, customer-facing organization, Cytology diagnosis, digital transformation, DNA Integration, Optimization, Practice Experience, Report (document), self-service

customer-facing organization; best practices; 2025 report; customer experience; self-service; AI integration; CX optimization; digital transformation

Eli Lilly Strikes $650M Deal with Juvena to Develop Muscle-Boosting Drugs

4 weeks ago talkbio0Tagged Administration occupational activities, Aortic Valve Insufficiency, biotech collaboration, Drug Development, Drug Discovery, Eli, Eli Lilly, muscle health, Muscle-Boosting Drugs, Obesity, stem cell-secreted proteins

Eli Lilly; Juvena Therapeutics; muscle-boosting drugs; AI drug discovery; muscle health; biotech collaboration; stem cell secreted proteins; drug development; obesity management; $650 million deal

Merck Wins FDA Approval for RSV Antibody Drug, Intensifying Market Competition

4 weeks ago talkbio0Tagged Approved, AstraZeneca, competition, Enflonsia, Infant, Market, Merck, Monoclonal Antibodies, Respiratory syncytial virus, sanofi, United States Food and Drug Administration

Merck; FDA approval; RSV; monoclonal antibody; infants; Enflonsia; competitive market; Sanofi; AstraZeneca

FDA Reinstates Generic Drug Policy Group After April Firings

4 weeks ago talkbio0Tagged Administrative action, Departure - action, development aspects, drug price, Generic Drugs, layoffs, Office, Policy, reinstatement, Transection (procedure), United States Food and Drug Administration

FDA; generic drugs; policy office; Division of Policy Development; reinstatement; layoffs; drug prices; administrative leave

Insmed’s ‘Unprecedented’ Phase 2 PAH Results Propel Stock and Next-Phase Plans

4 weeks ago talkbio0Tagged Clinical Trials, Insmed, PAH, Phase 3 trial, Pulmonary arterial hypertension, surge, TPTE2 gene, treprostinil palmitil inhalation powder

Insmed; PAH; TPIP; Phase 2b; clinical trial; treprostinil palmitil inhalation powder; stock surge; pulmonary arterial hypertension; Phase 3 trial; biotech

Recursion and Genentech Announce Significant Staff Layoffs in 2025

4 weeks ago talkbio0Tagged Biotech Layoffs, Drug Industry, genentech, pipeline cutbacks, Recursion

Recursion Pharmaceuticals; Genentech; biotech layoffs; workforce reduction; pipeline cutbacks; biotech funding; pharmaceutical industry; 2025 layoffs